Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4232 (Published 03 November 2020) Cite this as: BMJ 2020;371:m4232
In this paper by Agarwal and colleagues (BMJ 2020;371:m3939, doi:10.1136/bmj.m3939, published 22 October 2020), the details for reference 22 should be: R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis. World Health Organization; 2020 https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. (Accessed on 25 Aug 2020.) Also, the citation for reference 28 should appear at the end of the first paragraph of the strengths and limitations section of the discussion: “Although this approach could have affected comparability across study sites, we believe this lends the trial more generalisability, approximates real world scenarios more closely, and in the methodological spectrum of clinical trials, shifts it towards pragmatic trials.28”
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.